Lexicon Pharmaceuticals仅预告将于8月6日公布二季度财报

Lexicon Pharmaceuticals to Report Second Quarter 2026
Accessibility: Skip TopNav
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
July 30, 2026 08:30 ET
| Source:
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) --
(Nasdaq: LXRX) today announced the Company will release its second quarter 2026 financial results on Thursday, August 6, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.
Participants can access the conference call live via webcast on the Events page of the Company’s website at
https://investors.lexpharma.com/
. Participants who wish to ask a question may
register here
to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast will be available on the Lexicon website.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit
www.lexpharma.com
.
For Media Inquiries:
Dave Belian
lexinvest@lexpharma.com
For Investor Inquiries:
Lisa DeFrancesco
Tags
Lexicon
Lexicon Pharmaceuticals
Hypertrophic Cardiomyopathy
diabetes
Sotagliflozin
GlobeNewswire
Recommended Reading
July 27, 2026 08:30 ET
|
Source:
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
Study substantially exceeded enrollment target of 500 patients Topline results anticipated in Q1 2027 THE WOODLANDS, Texas, July 27, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc....
Read More
June 03, 2026 08:00 ET
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
THE WOODLANDS, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will present data from clinical studies of sotagliflozin in Type 1...